Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -130.82 Million USD | -1.75% |
| 2022 | -128.57 Million USD | -92.02% |
| 2021 | -66.95 Million USD | -116.67% |
| 2020 | -30.9 Million USD | 63.42% |
| 2019 | -84.49 Million USD | -53.77% |
| 2018 | -54.94 Million USD | -45.4% |
| 2017 | -37.79 Million USD | 22.31% |
| 2016 | -48.64 Million USD | -3.14% |
| 2015 | -47.15 Million USD | 23.1% |
| 2014 | -61.32 Million USD | -74.46% |
| 2013 | -35.15 Million USD | -83.6% |
| 2012 | -19.14 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -125.19 Million USD | 4.31% |
| 2024 Q3 | -446.6 Million USD | 34.01% |
| 2024 Q2 | -676.76 Million USD | -440.58% |
| 2023 Q4 | -130.82 Million USD | -59.69% |
| 2023 FY | -130.82 Million USD | -1.75% |
| 2023 Q1 | -57.23 Million USD | 55.48% |
| 2023 Q2 | -124.26 Million USD | -117.12% |
| 2023 Q3 | -81.92 Million USD | 34.07% |
| 2022 Q3 | -108.94 Million USD | -116.09% |
| 2022 Q1 | -104.9 Million USD | -56.67% |
| 2022 FY | -128.57 Million USD | -92.02% |
| 2022 Q4 | -128.57 Million USD | -18.02% |
| 2022 Q2 | -50.41 Million USD | 51.94% |
| 2021 Q4 | -66.95 Million USD | 16.01% |
| 2021 Q2 | -93.74 Million USD | 7.88% |
| 2021 FY | -66.95 Million USD | -116.67% |
| 2021 Q3 | -79.71 Million USD | 14.96% |
| 2021 Q1 | -101.76 Million USD | -229.31% |
| 2020 Q4 | -30.9 Million USD | 88.63% |
| 2020 FY | -30.9 Million USD | 63.42% |
| 2020 Q3 | -271.85 Million USD | -161.0% |
| 2020 Q2 | -104.15 Million USD | 33.51% |
| 2020 Q1 | -156.66 Million USD | -85.41% |
| 2019 FY | -84.49 Million USD | -53.77% |
| 2019 Q2 | -68.93 Million USD | -70.8% |
| 2019 Q3 | -79.6 Million USD | -15.48% |
| 2019 Q4 | -84.49 Million USD | -6.14% |
| 2019 Q1 | -40.35 Million USD | 26.55% |
| 2018 Q3 | -69.77 Million USD | -0.01% |
| 2018 Q1 | -74.42 Million USD | -96.93% |
| 2018 FY | -54.94 Million USD | -45.4% |
| 2018 Q4 | -54.94 Million USD | 21.25% |
| 2018 Q2 | -69.76 Million USD | 6.25% |
| 2017 Q2 | -29.59 Million USD | -25.39% |
| 2017 Q1 | -23.59 Million USD | 51.49% |
| 2017 Q4 | -37.79 Million USD | 27.8% |
| 2017 FY | -37.79 Million USD | 22.31% |
| 2017 Q3 | -52.34 Million USD | -76.88% |
| 2016 Q3 | -75.38 Million USD | -45.05% |
| 2016 Q4 | -48.64 Million USD | 35.48% |
| 2016 Q1 | -37.24 Million USD | 21.03% |
| 2016 FY | -48.64 Million USD | -3.14% |
| 2016 Q2 | -51.97 Million USD | -39.56% |
| 2015 Q3 | -332.82 Million USD | -366.03% |
| 2015 Q4 | -47.15 Million USD | 85.83% |
| 2015 Q2 | -71.41 Million USD | 29.15% |
| 2015 Q1 | -100.8 Million USD | -64.37% |
| 2015 FY | -47.15 Million USD | 23.1% |
| 2014 Q4 | -61.32 Million USD | 11.01% |
| 2014 Q1 | -143.61 Million USD | -308.58% |
| 2014 Q2 | -91.14 Million USD | 36.54% |
| 2014 FY | -61.32 Million USD | -74.46% |
| 2014 Q3 | -68.91 Million USD | 24.39% |
| 2013 Q2 | 9251.00 USD | -99.98% |
| 2013 FY | -35.15 Million USD | -83.6% |
| 2013 Q4 | -35.15 Million USD | 20.24% |
| 2013 Q1 | 45.31 Million USD | 389.64% |
| 2013 Q3 | -44.07 Million USD | -476502.68% |
| 2012 Q4 | -15.64 Million USD | 0.0% |
| 2012 FY | -19.14 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 7203.616% |
| Alpha Teknova, Inc. | 1.97 Million USD | 6727.609% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 238.874% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 274.555% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 130.052% |
| Cosmos Health Inc. | 8.59 Million USD | 1622.904% |
| Journey Medical Corporation | -9.7 Million USD | -1247.502% |
| Embecta Corp. | 1.31 Billion USD | 109.972% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 128.522% |
| Dynavax Technologies Corporation | 106.63 Million USD | 222.689% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 130.232% |
| PainReform Ltd. | -7.95 Million USD | -1545.648% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -736.789% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -736.789% |
| SCYNEXIS, Inc. | -19.35 Million USD | -576.119% |
| Safety Shot Inc | -2.28 Million USD | -5627.124% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -1287.41% |
| Procaps Group, S.A. | 242.93 Million USD | 153.854% |
| Theratechnologies Inc. | 24.87 Million USD | 626.03% |
| Harrow Health, Inc. | 116.41 Million USD | 212.38% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -5091.627% |
| Biofrontera Inc. | 4.05 Million USD | 3325.567% |
| DURECT Corporation | -7.65 Million USD | -1609.289% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -290.22% |
| Cronos Group Inc. | -663.32 Million USD | 80.277% |
| OptiNose, Inc. | 58.06 Million USD | 325.315% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 120.987% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -797.811% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -2422.719% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 971.438% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -1957.174% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 122531.428% |
| Radius Health, Inc. | 359.28 Million USD | 136.414% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 66440.279% |
| ProPhase Labs, Inc. | 19.23 Million USD | 780.303% |
| Phibro Animal Health Corporation | 454.84 Million USD | 128.763% |
| Procaps Group S.A. | 242.93 Million USD | 153.854% |
| Alvotech | 1.06 Billion USD | 112.292% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 3657.069% |
| Viatris Inc. | 17.13 Billion USD | 100.764% |
| Rockwell Medical, Inc. | 4.45 Million USD | 3036.019% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -2582.571% |
| SIGA Technologies, Inc. | -148.68 Million USD | 12.007% |
| Tilray Brands, Inc. | 158.97 Million USD | 182.294% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 207.327% |
| Shineco, Inc. | 29.29 Million USD | 546.663% |
| PetIQ, Inc. | 351.93 Million USD | 137.174% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -4409.124% |
| Incannex Healthcare Limited | -5.48 Million USD | -2285.214% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 173.79% |
| Alimera Sciences, Inc. | 55.3 Million USD | 336.542% |
| Silver Spike Investment Corp. | -32.61 Million USD | -301.173% |
| Assertio Holdings, Inc. | -32.52 Million USD | -302.192% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -8688.007% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -2485.357% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -2617.678% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -1492.858% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 3202.419% |
| Hempacco Co., Inc. | 13.61 Million USD | 1060.941% |
| Talphera, Inc. | -5.72 Million USD | -2186.82% |
| Alvotech | 1.06 Billion USD | 112.292% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 1931.057% |
| Lantheus Holdings, Inc. | -96.71 Million USD | -35.28% |
| Currenc Group, Inc. | -16.57 Million USD | -689.405% |
| Kamada Ltd. | -46.43 Million USD | -181.768% |
| Indivior PLC | -33.95 Million USD | -285.335% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 50308.002% |
| Flora Growth Corp. | -713 Thousand USD | -18249.088% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -1492.858% |
| Evolus, Inc. | 63.7 Million USD | 305.357% |
| HUTCHMED (China) Limited | -197.45 Million USD | 33.743% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 127.307% |
| Akanda Corp. | 3.9 Million USD | 3450.367% |